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The  ten-pneumococcal  conjugate  vaccine  (PCV10)  was  introduced  into  the  national  immunization  pro-
gram  for  childhood  vaccination  schedules  by  the  Brazilian  Health  Public  Service  in  March  2010.  The  aim
of this  study  was  to compare  Streptococcus  pneumoniae  serotype  distribution,  antibiotic  resistance  pat-
terns,  and  potential  coverage  before  (January  2006–June  2010)  and  after  (July  2010–September  2012)
PCV10  introduction.  The  incidence  of  invasive  pneumococcal  disease  (IPD),  patient  demographics,  and
disease  characteristics  were  recorded.  This  study  was  conducted  at  the  University  Hospital  of  Sao  Paulo
University  in  Brazil  from  January  2006  to  September  2012.  Serotyping  was  performed  using  multiplex
PCR  typing,  and  antimicrobial  sensitivity  by  Clinical  and  Laboratory  Standards  Institute  (CLSI).  A  total  of
259  S. pneumoniae  strains  were  isolated  from  patients  with  IPD.  The  ages  of  the  patients  ranged  from
3 months  to  95  years  old.  The  strains  were  isolated  from  cerebrospinal  ﬂuid,  pleural  ﬂuid,  and  blood.
The incidence  of  IPD  among  patients  at HU-USP  changed  after  the  introduction  of PCV10.  The  overall
incidence  of  IPD  was  3.42  cases  per  1000  admissions  in  the  vaccine  pre-  implementation  period  and  of
2.99  cases  per  1000  admissions  in  the  vaccine  post-implementation  period.  The  incidence  of  IPD among
children<2  y.o.  attended  at HU-USP  changed  signiﬁcantly  after  the  introduction  of  PCV10,  from  20.30
to 3.97  of  incidence.  The  incidence  of  PCV10-  serotypes  decrease  from  16.47  to  0.44  in  the  same  age,
before and  after  PC10  implementation,  respectively.  Moreover,  it  was  possible  to  realize  the  sensitiv-
ity to  penicillin  among  isolates  increased  signiﬁcantly  in  the  post-vaccine  period.  Data  from  this  study
suggest  that  PCV10  contributed  to decrease  with  PID  rate  among  children  less  than  2  y.o.  The  resistance
rate  among  pneumococcal  isolates  also  could  be observed  since  serotypes  with  greater  resistance  to  beta
lactam  antibiotics  were  not  easily  isolated  after  vaccination.
© 2013 Elsevier Ltd. All rights reserved.. Introduction
Streptococcus pneumoniae is the major cause of community-
cquired pneumonia, and it has been estimated that 13.8 million
neumonia cases occur worldwide each year, causing 90% of all
neumococcus-related deaths [1].
Pneumococcal disease accounted for 34,217 hospitalizations
rom 2004 to 2006 in the Brazilian National Health System. Pneu-
ococcal pneumonia accounts for 64.8% of these hospitalizations.
lthough the highest rates of this disease occur in children under
∗ Corresponding author at: University Hospital-USP, Brazil. Tel.: +55 1130919303;
ax: +55 1130919470.
E-mail addresses: mbmartin@usp.br, mabanez74@gmail.com (M.B. Martinez).
264-410X/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.vaccine.2013.05.042one year of age, the highest hospital case fatality rates occur among
the elderly, primarily resulting from sepsis and meningitis [2].
Ninety-three different capsular types of S. pneumoniae have
been detected to date. Despite this variety, only a select group
of serotypes are responsible for the majority of invasive disease,
particularly in children. Importantly, the prevalence of serotypes
may  vary according to demographic region and the period of study
[3]. Few serotypes demonstrate penicillin resistance, and these
serotypes are globally assigned to the 6B, 6A, 9V, 14, 15A, 19F, 23F,
and 19A serotypes, collectively called the “pediatric serotypes”.
Today, the 23-valent polysaccharide vaccine is used to vacci-
nate at-risk adults and the elderly. Unfortunately, immunization
with PPV has recently been found to be largely unsuccessful in
the elderly population. Conjugate vaccines have been designed to
improve efﬁcacy in children <2 years of age [4].
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PCV7 was ﬁrst recommended for use in the United States in
he year 2000. This vaccine contains the capsular polysaccharide
f seven serotypes conjugated to CRM197 (4, 6B, 9V, 14, 18C, 19F,
nd 23F), which were selected because they caused the majority
f invasive disease in the US at that time [5]. Additionally, these
erotypes are also associated with high antibiotic resistance [6,7].
Several authors report a sharp, sudden decline in IPD caused by
accine serotypes. This decrease occurs rapidly after the introduc-
ion of vaccination programs, both in the vaccinated children and
n all age groups [8–10]. Following the introduction of PCV7 in the
S, a shift in the prevalent serotypes circulating in the population
nd causing disease (termed serotype replacement) was observed
4].
Serotyping is required to monitor epidemiological trends
ollowing the introduction of serotype-speciﬁc polysaccharide con-
ugate vaccines, which include serotypes commonly encountered
n carriage and disease. The introduction of these vaccines has
ed to increased monitoring of the serotypes that cause invasive
isease. Additionally, there are reports of increases in disease
ncidences caused by non-PCV7 serotypes. Thus, new conjugate
accines PCV10 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, and 7F) and
CV13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, 7F, 3, 6A, and 19A) have
een introduced to replace PCV7 and expand protective coverage.
ontinuous surveillance is crucial to monitor vaccine efﬁcacy and
erotype replacement in different geographical regions [11].
In Brazil, PCV10 was introduced into the national immunization
rogram for the childhood vaccination schedule by the Brazil-
an Health Public Service in March 2010.The aim of this study
as to compare the incidence of IPD at our hospital, S. pneumo-
iae serotype distribution and antibiotic resistance patterns before
January 2006–June 2010) and after (July 2010–September 2012)
CV10 introduction.
. Materials and methods
The ten-pneumococcal conjugate vaccine (PCV10) was
ntroduced into the national immunization program for the
hildhood vaccination schedule by the Brazilian Health Public
ervice in March 2010. The vaccination schedule used in Brazil
s three doses in the ﬁrst six months of life, with a booster dose
t 12-15 months of age. Time periods encompassing pre-and
ost-implementation of PCV10 (January 2006 to June 2010 and
uly 2010 to September 2012, respectively) were examined.
This study was conducted at the University Hospital of Sao Paulo
niversity (HU-USP) in Brazil from January 2006 to September
012. This hospital attends people from Butantã, a region of São
aulo city with a population of approximately 408,000. The patients
ttended at the HU-USP belong to the Brazilian Health Public
ervice. The patients were stratiﬁed at least three age groups: chil-
ren (<2 y.o.), children (from 2 to <15 y.o.) and adult (>15 y.o.).
uring the study period, were admitted to intensive care unit and
he ward 3946 and 2264 children (<2 y.o.); 9245 and 5168 children
from 2 to <15 y.o.); 38,780 and 18,637 adults (>15 y.o.) before and
fter PCV10 introduction, respectively. A total of 259 patients were
iagnosed with invasive pneumococcal disease and S. pneumoniae
trains were isolated from cerebrospinal ﬂuid (36), pleural ﬂuid
24), and blood (199). The patients’ ages ranged from 3 months to
5 years old.
All pneumococcal strains were isolated from clinical specimens
ccording to Garcia and Isenberg [12]. Identiﬁcation of strains was
erformed in the Clinical Laboratory of HU-USP. Isolates were
ultured on blood agar medium with 5%CO2 at 35 ◦C and identi-
ed using conventional methods, including bile solubility testing,
ptochin sensitivity, and Vitek2 (BioMerieux®, France). 31 (2013) 6150– 6154 6151
All pneumococcal isolates were serotyped using sequential mul-
tiplex PCR typing [13,14]. Brieﬂy, a schematic sequence-based
system of six multiplex PCRs was used in a sequence order based
upon Active Bacterial Core surveillance (ABCs) serotype distribu-
tion during 2002 and 2003.The system was revised for optimal
targeting of prevalent serotypes in Latin America to reliably deduce
speciﬁc pneumococcal serotypes.
Antibiotic susceptibility testing was done following CLSI
guidelines [15]. All of the isolates were examined for antibiotic sus-
ceptibility against clindamycin, chloramphenicol, erythromycin,
rifampicin, tetracycline, trimethoprim-sulfamethoxazole, and
levoﬂoxacin by the disk-diffusion method (Oxoid, Cambridge,
UK). Penicillin and ceftriaxone resistance were veriﬁed using
the Etest (AB BIODISK, Solna, Sweden). The breakpoints used for
interpretation were those recommended by the CLSI in 2012.
Statistical analyses were performed using Fisher’s exact test as
appropriate. We  considered p < 0.05 to be signiﬁcant. All p values
are two sided. Statistical analyses were performed with Statistica
(version 6.1 StatSoft, Tulsa, OK, USA).
3. Results
During the study period, the HU-USP clinical laboratory recov-
ered 259 S. pneumoniae isolates from 259 IPD patients: 178 during
the pre-implementation PCV10 period and 81 during the post-
implementation period. The incidence of IPD among patients at
HU-USP changed after the introduction of PCV10. A signiﬁcantly
decline in overall IPD incidence (from 20.3 to 3.97 cases/1,000 peo-
ple) was observed in children with <2 years of age (p = 0.0012)
after introduction of PCV10. A decline but non-signiﬁcant was
seen in children from 2 to <15 years of age. IPD incidence
rates remained unchanged in people >15 y.o. (from 1.72 to 3.16
cases/1000 people, p = 0.4149). Comorbidities such as HIV, alco-
holism, and cirrhosis did not appear to inﬂuence the development
of IPD. Among the cases, 11% (20/178) had comorbidities in
the pre-implementation period, compared with 14% (11/81) in
the post-implementation period (p > 0.05). In the pre-vaccination
period, the rates of isolation of strains relative to age were as
follows: 44.4% (<2 y.o.), 11.2% (2–4 y.o.), 6.2% (5–14 y.o.), 24.7%
(15–60 y.o.), and 12,9% (>60 y.o.). The most signiﬁcant decrease
in IPD occurred in children <2 y.o. (p < 0.0012). After PCV10 intro-
duction, 11% of the strains were isolated from children <2 y.o. and
57% from adults (15–60 y.o.) (Table 1). Culture-conﬁrmed cases
of S. pneumoniae from IPD decreased by 46% overall after PCV10
introduction, conﬁrmed cases in children <2 y.o. decreased by 89%
(Table 1).
After introduction of PCV10, a clear reduction in IPD for those
serotypes contained in the vaccine was observed (Fig. 1). After
PCV10 vaccination, it is possible to observe a downward trend in
the incidence of PCV10 serotypes, a signiﬁcant reduction occurred
in the age group of 2 years old (from 16.47 to 0.44 cases/1000 peo-
ple (p < 0.0002). However, no signiﬁcant increase was observed in
the adults (people >15 y.o.). Non-PCV 10 serotypes incidence rates
remained unchanged in all age group (Table 1).
In the period preceding PCV10 introduction, the most frequently
isolated serotypes among patients of all ages were serotypes 14
(0.92 cases/1000 people), 5 (0.45 cases/1000 people), 6B (0.31
cases/1000 people), 12F (0.34 cases/1000 people), and 1 (0.17
cases/1000 people). After the introduction of the vaccine, serotype
7F was the most frequently isolated (0.50 cases/1,000 people),
followed by 8 (0.43 cases/1,000 people), 12F (0.40 cases/1,000 peo-
ple), and 3 (0.37 cases/1000 people). Among children <2 y.o. with
IPD, 79% were infected with S. pneumoniae belonging to a vaccine
serotype during the pre-vaccination period. After PCV10 intro-
duction, 11% of children <2 y.o. were infected with one vaccine
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Table 1
Distribution of clinical invasive pneumococcal disease before and after PCV10 implementation.
Vaccination periodsb
Age group (year) Pre-implementation Post-implementation
No. of cases Incidencea No. of cases Incidencea p
All serotypes
All ages 178 3.49 81 2.99 NS
<2  80 20.30 9 3.97 <0.0012
=2  < 15 31 3.35 13 2.52 NS
>15  67 1.72 59 3.16 NS
PCV10  serotypes
All ages 124 2.38 27 1.03 NS
<2  65 16.47 1 0.44 0.0002
=2  < 15 26 2.81 5 0.97 NS
>15  33 0.85 21 1.13 NS
Non-PCV 10 serotypes
All ages 54 1.04 51 1.95 NS
<2  15 3.80 7 3.11 NS
=2  < 15 5 5.41 7 1.35 NS
>15  34 0.88 37 1.98 NS
a Incidence is number of cases/1000 people; NS: not signiﬁcant.
b Vaccination periods: pre-implementation period, January 2006–June 2010; post-implementation period, July 2010–September 2012. Statistical analyses were performed
using  Fisher’s exact test as appropriate. We  considered p < 0.05 to be signiﬁcant. All p values are two sided. Statistical analyses were performed with Statistica (version 6.1
StatSoft, Tulsa, OK, USA).
Table 2
Pneumococcal serotype distribution in children <2, children 2 to <15, and adults ≥15 years old.
Vaccination periodsa
Age groups (y.o.) Before After Before After
PCV10 serotypesb
(incidence)
PCV10 serotypesb
(incidence)
PCV10 non-serotypesc
(incidence)
PCV10 non-serotypesc
(incidence)
<2 5 (1.27), 6B (3.04), 14
(9.38)*
14 (0.45)* 6A (0.25), 10A (0.25),
19A (1.01)
10A (0.44), 22F (0.90)
2  to<15 1(0.54), 5(1.10), 14
(0.65)
1 (0.39), 5(0.19), 14
(0.19)
3 (0.43), 19A (0.10) 3 (0.39), 19A (0.19)
≥15  5 (0.21), 7F(0.10),
14(0.13)
5 (0.08), 7F(0.46),
14(0.15)
3(0.15), 8 (0.05)*, 12F
(0.36)
3(0.16), 8 (0.59)*, 12F
(0.48)
Incidence is number of cases/1000 people.
a Vaccination periods: Before, January 2006–June 2010; After, July 2010–September 2012.
b Three most prevalent PCV10 serotypes.
c Three most prevalent non-PCV10 serotypes.
* p < 0.05. Statistical analyses were performed using Fisher’s exact test as appropriate. W
were  performed with Statistica (version 6.1 StatSoft, Tulsa, OK, USA).
Fig. 1. Percentage of isolates belonging to PCV10 serotypes and non-PCV10
s
i
2
s
a
serotypes in the pre-implementation and post-implementation periods. Pre-
mplementation period, January 2006–June 2010; post-implementation period, July
010–September 2012. ***p < 0.0001; all p values are 2 sided.erotype, 14. Data on the serotype distribution of IPD in different
ge groups are summarized in Table 2.
A total of 259 S. pneumoniae strains were examined for antibiotic
usceptibility. Among the pre-vaccination and post-vaccinatione considered p < 0.05 to be signiﬁcant. All p values are two sided. Statistical analyses
strains, no trend in increasing antimicrobial susceptibility
was observed for clindamycin, chloramphenicol, erythromycin,
rifampicin, tetracycline, or levoﬂoxacin (p > 0.05), but susceptibil-
ity to trimethoprim-sulfamethoxazole increased from 31 to 68%
(group <15 y.o.) and 64 to 88% (group >15 y.o.) after introduction
of PCV10 (p < 0.002). The sensitivity to penicillin and ceftriaxone
increased signiﬁcantly in the post-vaccine period. In all age group
the number of strains isolated with penicillin MIC  <0.06 g/ml
increased after vaccination period, from 47.7 to 77.3% (<15 y.o;
p = 0.04) and from 80.6 to 94.8% (>15 y.o.; p = 0.03). The sensitivity
of pneumococci to ceftriaxone increased signiﬁcantly in pediatric
patients in the post-vaccine period. The percentage of pneumococci
with MIC  less than 0.05 g/ml increased in the post-vaccination
period, from 71.6% to 95.5% (< 15 y.o.; p = 0.02). No signiﬁcance was
observed among isolates from adults (<15 y.o.) (Tables 3 and 4).
4. Discussion
The S. pneumoniae is a predominant cause of community-
acquired pneumonia, exacerbation of chronic bronchitis,
meningitis, sinusitis, and bacteremia in both developed and
developing countries. The WHO  estimates that out of the approxi-
mately 8.8 million global annual deaths among children <5 years in
2008, 476,000 (333,000-529,000) were caused by pneumococcal
S.R. dos Santos et al. / Vaccine 31 (2013) 6150– 6154 6153
Table 3
Penicillin susceptibility proﬁle before and after introduction of PCV10.
Vaccination periodsa
MIC  (g/ml) <15 years old >15 years old
Pre-vaccination Post-vaccination Pre- vaccination Post-vaccination
N % N % p N % N % p
≤0.06 53 47.7 17 77.3 0.04 54 80,6 55 94,8 0.03
0.12-2 56 50.5 4 18.2 0.21 13 19,4 3 5,2 0.56
≥4  2 1.8 1 4.5 0 0 0 0
Total  111 22 67 58
a Vaccination periods: pre-vaccination period, January 2006–June 2010; post-vaccination period, July 2010–September 2012. MIC: minimal inhibitory concentration.
Statistical analyses were performed using Fisher’s exact test as appropriate. We considered p < 0.05 to be signiﬁcant. All p values are two sided. Statistical analyses were
performed with Statistica (version 6.1 StatSoft, Tulsa, OK, USA).
Table 4
Ceftriaxone susceptibility proﬁle before and after introduction of PCV10.
MIC  (g/ml) <15 years old >15 years old
Pre-vaccination* Post-vaccination* Pre-vaccination Post-vaccination
N % N % p N % N % p
≤0.05 73 71.6 21 95.5 0.02 61 96.8 58 100 0.19
1  28 27.5 1 4.5 0.044 2 3.2 0 0 0.19
≥2  1 0.9 0 0 0 0 0 0 0
Total  102 22 63 58
* tion p
a  < 0.0
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nalyses were performed using Fisher’s exact test as appropriate. We  considered p
ith  Statistica (version 6.1 StatSoft, Tulsa, OK, USA).
nfections. In developing countries, case-fatality rates among
ounger infants may  reach 20% for pneumococcal septicemia and
0% for meningitis [16].
A recent review of randomized, controlled trials of PCV7 found a
accine efﬁcacy (VE) against invasive pneumococcal disease of 71%.
ased on immunogenicity data, PCV10 shows a comparable VE for
erotypes contained in the vaccine [16].
In the present study, the incidence of IPD was reduced by 80% in
hildren younger than two years after the introduction of PCV10In
he period preceding vaccine introduction, serotype 14 was  the
ost common in this age group, followed by 6B. After PCV10 was
ntroduced in Brazil by the Brazilian Health Public Service, there
as a decrease in the vaccine serotypes isolated from patients
ith IPD who were attended at HU-USP. Even in other age groups
>2y.o.), it is possible to observe a decreasing trend in the inci-
ence of PCV10 serotypes. However, no signiﬁcant increase was
bserved in the overall incidence of non-PCV10 serotype IPD. It
s interesting to highlight that the incidence of serotype 19A in
he period post-vaccination did not increase as showed by other
tudies [17,18]. In pediatric patients (<15 y.o.) this serotype was
dentiﬁed in ﬁve cases in the pre-vaccination period and only one
n the period following vaccination. In adults (>15 y.o.), two and one
ases were identiﬁed in the pre-vaccination and post-vaccination
eriod, respectively.
Here, it is interesting to note that the shift in pneumococcal
erotypes isolated was so pronounced that the order of the sequen-
ial multiplex PCR array had to be rearranged. The most strains
solated prior to the vaccination period were typed using sequential
eaction number one, in which 46% of strains were typed. How-
ver, the majority of isolates after the vaccination period (50%)
ere typed using sequential multiplex PCR typing number three,ollowed by number four.
From 1993 to 1999 in Brazil, 63 serotypes were identiﬁed among
,858 cases of invasive pneumococcal disease [18]. Eleven capsular
erotypes were responsible for 86% of these cases. The serotypeseriod, July 2010–September 2012. MIC: minimal inhibitory concentration. Statistical
5 to be signiﬁcant. All p values are two  sided. Statistical analyses were performed
14 (33%), 1 (12%), 5 (11%), 6A/6B (11%), 23F (4.%), and 19A (4%)
displayed a strong association with pneumonia [18]. A study con-
ducted in Latin America from 2000 to 2005 conﬁrms that the most
common serotypes in Brazil were 14 (49%), 1 (13%), and 6B (8%)
[19]. In other studies, similar serotype distributions were observed
[20,21].
Despite the use of antimicrobial treatments, the rates of
pneumococcal resistance to non-meningeal infections are low.
Additionally, treatment failure for pneumococcal pneumonia has
not previously been reported. Data from this study suggest that
PCV10 contributed to the decrease in the resistance rate among
pneumococcal isolates because serotypes of strains with higher
resistance rates to beta lactam antibiotics were poorly isolated
after vaccination. Similar results are also observed in countries that
introduced PCV7 in the 2000s. Further, it was found that the rate
of resistance to penicillin signiﬁcantly declined in these studies
[22–24].
The number of patients in our study represents only a small
portion of vaccinated Brazilian children, and the study period was
too short to enable us to draw ﬁrm conclusions about changes in
serotype-speciﬁc incidence. However, these data are the ﬁrst from
Brazil examining the effects of PCV10 on IPD. Moreover, these data
are useful because the epidemiology of IPD in developing countries
differs from that in other parts of the world.
The rapid introduction of PCVs in developing countries has
much support. The incidence of disease in these areas should
be monitored following the introduction of vaccines to investi-
gate their effects on disease prevalence. According to the WHO,
the impact of PCV should be carefully monitored as part of
a routine sentinel surveillance system. Available evidence does
not suggest that serotype replacement is an impediment to PCV
introduction [25]. However, the occurrence and magnitude of
serotype replacement should be monitored through carefully con-
ducted surveillance studies, including in low-income settings
[16].
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. Conclusion
In the present study, the incidence of vaccine serotypes
ecreased from 2.38 to 1.03 following PCV10 introduction. A signiﬁ-
antly decline in overall IPD incidence (from 20.3 to 3.97 cases/1000
eople) was observed in children with <2 years of age (p = 0.0012)
fter introduction of PCV10. Data from this study suggest that
CV10 contributed to the decrease in the resistance rate among
neumococcal isolates because serotypes of strains with higher
esistance rates to beta lactam antibiotics were poorly isolated after
accination.
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